Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

1.

Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.

Khanwelkar RR, Chen GS, Wang HC, Yu CW, Huang CH, Lee O, Chen CH, Hwang CS, Ko CH, Chou NT, Lin MW, Wang LM, Chen YC, Hseu TH, Chang CN, Hsu HC, Lin HC, Shih YC, Chou SH, Tseng HW, Liu CP, Tu CM, Hu TL, Tsai YJ, Chern JW.

Bioorg Med Chem. 2010 Jul 1;18(13):4674-86. doi: 10.1016/j.bmc.2010.05.021. Epub 2010 May 12.

PMID:
20570526
[PubMed - indexed for MEDLINE]
2.

Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.

Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.

J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. doi: 10.1124/jpet.112.197087. Epub 2012 Aug 30.

PMID:
22935731
[PubMed - indexed for MEDLINE]
Free Article
3.

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.

Showalter HD, Sercel AD, Leja BM, Wolfangel CD, Ambroso LA, Elliott WL, Fry DW, Kraker AJ, Howard CT, Lu GH, Moore CW, Nelson JM, Roberts BJ, Vincent PW, Denny WA, Thompson AM.

J Med Chem. 1997 Feb 14;40(4):413-26.

PMID:
9046331
[PubMed - indexed for MEDLINE]
4.

Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.

Mahboobi S, Uecker A, Sellmer A, Cénac C, Höcher H, Pongratz H, Eichhorn E, Hufsky H, Trümpler A, Sicker M, Heidel F, Fischer T, Stocking C, Elz S, Böhmer FD, Dove S.

J Med Chem. 2006 Jun 1;49(11):3101-15.

PMID:
16722630
[PubMed - indexed for MEDLINE]
5.

N-phenyl-N'-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases.

Oguro Y, Miyamoto N, Takagi T, Okada K, Awazu Y, Miki H, Hori A, Kamiyama K, Imamura S.

Bioorg Med Chem. 2010 Oct 15;18(20):7150-63. doi: 10.1016/j.bmc.2010.08.042. Epub 2010 Aug 25.

PMID:
20833551
[PubMed - indexed for MEDLINE]
6.

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

Boschelli DH, Wu Z, Klutchko SR, Showalter HD, Hamby JM, Lu GH, Major TC, Dahring TK, Batley B, Panek RL, Keiser J, Hartl BG, Kraker AJ, Klohs WD, Roberts BJ, Patmore S, Elliott WL, Steinkampf R, Bradford LA, Hallak H, Doherty AM.

J Med Chem. 1998 Oct 22;41(22):4365-77.

PMID:
9784112
[PubMed - indexed for MEDLINE]
7.

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.

Schroeder MC, Hamby JM, Connolly CJ, Grohar PJ, Winters RT, Barvian MR, Moore CW, Boushelle SL, Crean SM, Kraker AJ, Driscoll DL, Vincent PW, Elliott WL, Lu GH, Batley BL, Dahring TK, Major TC, Panek RL, Doherty AM, Showalter HD.

J Med Chem. 2001 Jun 7;44(12):1915-26.

PMID:
11384237
[PubMed - indexed for MEDLINE]
8.

Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.

Cho TP, Dong SY, Jun F, Hong FJ, Liang YJ, Lu X, Hua PJ, Li LY, Lei Z, Bing H, Ying Z, Qiong LF, Bei FB, Guang LL, Shen GA, Hong SG, Hong SW, Tai MX.

J Med Chem. 2010 Nov 25;53(22):8140-9. doi: 10.1021/jm101036c. Epub 2010 Oct 28.

PMID:
21028894
[PubMed - indexed for MEDLINE]
9.

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.

Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.

Mol Cancer Ther. 2006 May;5(5):1280-9.

PMID:
16731761
[PubMed - indexed for MEDLINE]
Free Article
10.

Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.

Li Y, Tan C, Gao C, Zhang C, Luan X, Chen X, Liu H, Chen Y, Jiang Y.

Bioorg Med Chem. 2011 Aug 1;19(15):4529-35. doi: 10.1016/j.bmc.2011.06.022. Epub 2011 Jun 16.

PMID:
21724404
[PubMed - indexed for MEDLINE]
11.

Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases.

Zaman GJ, Vink PM, van den Doelen AA, Veeneman GH, Theunissen HJ.

Biochem Pharmacol. 1999 Jan 1;57(1):57-64.

PMID:
9920285
[PubMed - indexed for MEDLINE]
12.

Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases.

Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Furet P, Mestan J, Meyer T.

Bioorg Med Chem Lett. 2004 Dec 6;14(23):5793-7.

PMID:
15501042
[PubMed - indexed for MEDLINE]
13.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

PMID:
15256466
[PubMed - indexed for MEDLINE]
Free Article
14.

Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.

Dai Y, Guo Y, Frey RR, Ji Z, Curtin ML, Ahmed AA, Albert DH, Arnold L, Arries SS, Barlozzari T, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Pease LJ, Stewart KD, Stoll VS, Tapang P, Wishart N, Davidsen SK, Michaelides MR.

J Med Chem. 2005 Sep 22;48(19):6066-83.

PMID:
16162008
[PubMed - indexed for MEDLINE]
15.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099
[PubMed - indexed for MEDLINE]
16.

Response to sunitinib malate in advanced alveolar soft part sarcoma.

Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S.

Clin Cancer Res. 2009 Feb 1;15(3):1096-104. doi: 10.1158/1078-0432.CCR-08-2050.

PMID:
19188185
[PubMed - indexed for MEDLINE]
Free Article
17.

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM.

Clin Cancer Res. 2003 Jan;9(1):327-37.

PMID:
12538485
[PubMed - indexed for MEDLINE]
Free Article
18.

The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.

Ning S, Laird D, Cherrington JM, Knox SJ.

Radiat Res. 2002 Jan;157(1):45-51.

PMID:
11754641
[PubMed - indexed for MEDLINE]
19.

Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase.

Kubo K, Ohyama S, Shimizu T, Takami A, Murooka H, Nishitoba T, Kato S, Yagi M, Kobayashi Y, Iinuma N, Isoe T, Nakamura K, Iijima H, Osawa T, Izawa T.

Bioorg Med Chem. 2003 Nov 17;11(23):5117-33.

PMID:
14604675
[PubMed - indexed for MEDLINE]
20.

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.

Cancer Res. 2000 Aug 1;60(15):4152-60.

PMID:
10945623
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk